Mounjaro's effect on fertility: what we know, what's uncertain, and who to ask

If you're trying to conceive right now, the answer is clear

Mounjaro is contraindicated in pregnancy, and the current clinical position is that treatment should stop before you start trying to conceive. The reasoning is precautionary rather than based on confirmed harm in humans, there is simply not enough data from human pregnancies on tirzepatide to establish safety, and the animal study findings were concerning enough for the MHRA and the medicine's licence to state clearly that it should not be used. NHS England's guidance on weight-management injections reinforces this: women who are pregnant, breastfeeding, or planning a pregnancy should not be on this treatment.

The practical question, how far in advance should you stop?, is one for your prescriber or GP rather than a fixed rule you can apply yourself. Wash-out periods depend on how long the medicine has been in your system, your current dose, and your individual health picture. A named clinician who knows your history is the right person to work that out with you. If you're at the planning stage, raising it now, before you start trying, gives you more options than raising it after a positive test.

For more detail on this specific question, the page on how Mounjaro affects fertility in women covers the hormonal mechanisms and the evidence base in greater depth.

If you're not planning a pregnancy but fertility is still on your mind

This is the situation where the picture is genuinely more nuanced. Obesity is associated with hormonal disruption, elevated oestrogen, suppressed ovulation, and in conditions like polycystic ovary syndrome (PCOS), the kind of insulin resistance that tirzepatide directly addresses through its dual GIP and GLP-1 receptor action. Some people find that meaningful weight loss restores menstrual regularity and ovulation before they expect it to, which is clinically plausible and worth taking seriously.

The implication is practical: effective contraception matters. The MHRA advises women of childbearing age to use reliable contraception throughout treatment. For women taking the oral contraceptive pill, there is an additional step: because Mounjaro slows gastric emptying, pill absorption may be reduced during the first four weeks of treatment and for four weeks after each dose increase. NHS guidance recommends adding a non-oral method (condoms, for example) during those windows. This is distinct from the guidance for semaglutide (Wegovy), where no equivalent interaction evidence has been identified. You can read more about this on the tirzepatide and fertility overview.

If your contraceptive method is non-oral (a coil, implant, patch, injection, or ring), this interaction concern doesn't apply in the same way, though discussing any changes to your contraception with your GP remains sensible.

What weight loss itself may do to reproductive hormones

It is worth separating two things: what tirzepatide does as a medicine, and what losing a significant amount of weight does to the body's hormonal environment. The second of these has a longer evidence base. Adipose tissue produces oestrogen; visceral fat drives insulin resistance; both affect the hormonal signals that regulate ovulation. Reducing excess weight through any means tends to move these markers in a more favourable direction.

In the context of conditions like PCOS, weight loss of 5–10% of body weight has been associated with restored ovulation in some studies, a figure that many people on tirzepatide reach within the first few months of treatment. The Mounjaro and fertility page looks at what the current literature says about this specifically, including the limitations of the research. For men, the picture is different but similarly emerging, Mounjaro's potential effects on male fertility are explored separately, as sperm quality and testosterone levels are affected by obesity through distinct pathways.

None of this constitutes a guarantee of improved fertility, and the direct question of whether Mounjaro affects fertility does not yet have a definitive clinical answer. Trials were not designed to measure conception rates as primary endpoints.

How to approach this with a prescriber

The conversation about fertility and Mounjaro is one that our prescribers are asked about regularly. Every consultation at nume's treatment service involves a personal clinical review, your answers are read by a GPhC-registered Independent Prescriber, not processed automatically. If your circumstances include fertility planning, contraception questions, or a condition like PCOS, that context shapes the clinical assessment.

For people transferring from another provider, or asking about dose changes alongside these concerns, the review process at our pharmacy requires evidence of current treatment and considers your full health picture before anything is dispatched. When treatment is approved, it arrives by tracked DPD delivery the next working day in plain, unbranded packaging, the pen itself is the Mounjaro KwikPen, clearly labelled, with a patient information leaflet inside that covers contraception and pregnancy guidance in full. That leaflet, and the NHS England guidance on weight-management injections, are the right starting points for the factual detail.

If your situation is more complex (a fertility investigation under way, IVF being considered, or a recent pregnancy) the right route is a conversation with your GP or a reproductive specialist alongside any prescriber review. Our clinical team, led by our clinical lead, can work alongside that, but they do not replace specialist reproductive medicine input. Questions about other lifestyle factors on Mounjaro or about what treatment costs can be answered separately once the clinical picture is clearer. If you have questions before starting, our FAQs cover many of the practical points, and the team is reachable through the contact page seven days a week.